Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company Drug

Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials

Fineline Cube Jul 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...

Company Drug

Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004

Fineline Cube Jul 18, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...

Company Drug

Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales

Fineline Cube Jul 18, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...

Company Deals

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu

Fineline Cube Jul 18, 2025

Shandong Buchang Chuanfang, a subsidiary of China-based Buchang Pharma (SHA: 603858), announced the establishment of...

Company

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands

Fineline Cube Jul 17, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income...

Company Drug

Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials

Fineline Cube Jul 17, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...

Company Deals

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market

Fineline Cube Jul 17, 2025

China-based PHASE Scientific has entered into an exclusive distribution agreement with Lumos Diagnostics to introduce...

Company Drug

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Fineline Cube Jul 17, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...

Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Fineline Cube Jul 17, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting...

Company Policy / Regulatory

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Fineline Cube Jul 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China’s Center for Drug...

Company Drug

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Fineline Cube Jul 17, 2025

Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...

Company Drug

Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy

Fineline Cube Jul 17, 2025

France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...

Company Deals

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development

Fineline Cube Jul 16, 2025

China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40...

Company Drug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Fineline Cube Jul 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Drug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Fineline Cube Jul 16, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Deals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

Fineline Cube Jul 16, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...

Company Drug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Fineline Cube Jul 16, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...

Company Medical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

Fineline Cube Jul 16, 2025

Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced that it has received the marketing license...

Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

Fineline Cube Jul 16, 2025

China’s National Medical Products Administration (NMPA) has released the 94th batch of reference drugs for...

Company Deals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal

Fineline Cube Jul 16, 2025

US major Becton, Dickinson and Co., (BD) is set to merge its Biosciences & Diagnostic...

Posts pagination

1 … 169 170 171 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.